Jiunn Song

Jiunn Song

Auto-generated profile, based on publicly available information

Jiunn Song

Harvard Medical School, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2022 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
JSJiunn Song
Jiunn Song
AMArda Mizrak
Arda Mizrak
CLChia-Wei Lee
Chia-Wei Lee
MCMarcelo Cicconet
Marcelo Cicconet
ZLZon Weng Lai
Zon Weng Lai
TWTobias C. Walther
Tobias C. Walther
Pathways localizing proteins to their sites of action are essential for eukaryotic cell organization and function. Although mechanisms of protein targeting to many organelles have been defined, how proteins, such as metabolic enzymes, target from the endoplasmic reticulum (ER) to cellular lipid droplets (LDs) is poorly understood. Here we identify two distinct pathways for ER-to-LD protein targeting: early targeting at LD formation sites during formation, and late targeting to mature LDs after their formation. Using systematic, unbiased approaches inDrosophilacells, we identified specific membrane-fusion machinery, including regulators, a tether and SNARE proteins, that are required for the late targeting pathway. Components of this fusion machinery localize to LD–ER interfaces and organize at ER exit sites. We identified multiple cargoes for early and late ER-to-LD targeting pathways. Our findings provide a model for how proteins target to LDs from the ER either during LD formation or by protein-catalysed formation of membrane bridges.

14 April 2023 in Hepatology Communications
Verified
Journal Article
Open access
JSJiunn Song
Jiunn Song
ZJZ. Gordon Jiang
Z. Gordon Jiang
Introduction: Vitamin A, a fat-soluble vitamin that includes retinol and carotenoids, is implicated in liver fibrosis, whereas its deficiency has been associated with various liver diseases and higher overall mortality. This study aims to determine the relationship between levels of vitamin A species and liver fibrosis, as well as liver-related mortality in the population of the US. Methods: A total of 12,299 participants from the National Health and Nutrition Examination Survey III (NHANES III) were analyzed to provide nationally representative estimates of the relationship between the levels of vitamin A species and liver fibrosis measured by Fibrosis-4 (FIB-4) index and liver-related mortality. Results: A low blood level of retinol, but not other retinoid derivatives, was associated with significant liver fibrosis after adjustment for demographics, anthropometric measurements, medical history, retinol, and carotene intakes. Compared with vitamin D and E, retinol deficiency demonstrated much stronger associations with a high FIB-4 score. Individuals with known risks of chronic liver disease (CLD) and the lowest pentile of retinol levels had ORs of 3.12 (95% CI, 1.64–5.91) for possible fibrosis and 19.7 (95% CI, 5.71–67.7) for likely fibrosis, and an HR of 7.76 (95% CI, 1.19–50.5) for liver-related mortality compared with those in the highest retinol-level pentile. These relationships were more pronounced among individuals with known risks of chronic liver disease than without. Conclusions: A low circulating retinol level is associated with liver fibrosis and liver-related mortality in chronic liver disease. This relationship is potentially driven by a mechanistic link rather than the malabsorption of fat-soluble vitamins and may be leveraged for disease prognostication and have therapeutic implications. Export

20 April 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
JSJiunn Song
Jiunn Song
ZJZ. Gordon Jiang
Z. Gordon Jiang

15 September 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
JSJiunn Song
Jiunn Song
AMArda Mizrak
Arda Mizrak
CLChia-Wei Lee
Chia-Wei Lee
MCMarcelo Cicconet
Marcelo Cicconet
ZLZon Weng Lai
Zon Weng Lai
TWTobias C. Walther
Tobias C. Walther
Pathways localizing proteins to their sites of action within a cell are essential for eukaryotic cell organization and function. Although mechanisms of protein targeting to many organelles have been defined, little is known about how proteins, such as key metabolic enzymes, target from the ER to cellular lipid droplets (LDs). Here, we identify two distinct pathways for ER-to-LD (ERTOLD) protein targeting: early ERTOLD, occurring during LD formation, and late ERTOLD, targeting mature LDs after their formation. By using systematic, unbiased approaches, we identified specific membrane-fusion machinery, including regulators, a tether, and SNARE proteins, that are required for late ERTOLD targeting. Components of this fusion machinery localize to LD-ER interfaces and appear to be organized at ER exit sites (ERES) to generate ER-LD membrane bridges. We also identified multiple cargoes for early and late ERTOLD. Collectively, our data provide a new model for how proteins target LDs from the ER. HIGHLIGHTS Proteins localize to LDs either during formation or later through ER-LD bridges Specific membrane fusion machinery localizes to LDs and mediates protein targeting Specific ER exit site proteins associate with LDs and participate in ERTOLD targeting Proteomic studies reveal cargoes for early and late ERTOLD targeting

16 December 2025 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
JCJonggi Choi
Jonggi Choi
VNVy H. Nguyen
Vy H. Nguyen
EPEric Przybyszewski
Eric Przybyszewski
JSJiunn Song
Jiunn Song
ACAllison Carroll
Allison Carroll
RCRaymond T. Chung
Raymond T. Chung
INTRODUCTION: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are widely prescribed for type 2 diabetes mellitus (T2DM) and may confer hepatoprotective effects. This study investigated their association with hepatocellular carcinoma (HCC) risk compared with other antidiabetic medications. METHODS: We conducted a retrospective cohort study using the electronic health records from Mass General Brigham (Boston, USA) and Asan Medical Center (Seoul, Korea) from 2013 to 2024. Adults with T2DM newly initiating SGLT2i, dipeptidyl peptidase-4 inhibitor (DPP4i), glucagon-like peptide-1 receptor agonist (GLP-1RA), or sulfonylureas were included. A 6-month landmark analysis was used to minimize early event bias. Inverse probability weighting combined with Fine-Gray competing risk models estimated subdistribution hazard ratios (SHRs) for incident HCC, accounting for transplant and death as competing events. RESULTS: After weighting, data from 6,733 SGLT2i, 4,495 GLP-1RA, 23,229 DPP4i, and 17,034 sulfonylurea initiators were analyzed. Over a median follow-up of 3.9 years (277,155 person-years), 623 HCC cases occurred. SGLT2i use was associated with significantly lower HCC risk vs sulfonylureas (SHR 0.44, 95% confidence interval [CI]: 0.25–0.79) and DPP4i (SHR 0.53, 95% CI: 0.30–0.93). The comparison with GLP-1RA showed comparable risk (SHR 0.87, 95% CI: 0.40–1.91). Subgroup analyses demonstrated consistent protective associations of SGLT2i in patients aged 65 years and younger, men, and those with chronic liver disease. Sensitivity analyses, including 12-month landmark analysis and adjustments for additional confounders, confirmed robustness of findings. DISCUSSION: SGLT2 inhibitor therapy was associated with reduced risk of HCC compared with DPP4 inhibitors and sulfonylureas, supporting their potential chemopreventive role in patients with T2DM.

12 May 2026 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
EAErik Almazan
Erik Almazan
JCJonggi Choi
Jonggi Choi
TKTushar Kamath
Tushar Kamath
VNVy H. Nguyen
Vy H. Nguyen
EPEric Przybyszewski
Eric Przybyszewski
RCRaymond T. Chung
Raymond T. Chung
INTRODUCTION: Randomized clinical trials indicate that glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment improves histologic endpoints in steatotic liver disease, but its effects on long-term clinical outcomes remain uncertain. We examined the association between GLP-1 RA use and hepatic complications in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes mellitus (T2DM). METHODS: We conducted a retrospective, new-user cohort study emulating sequential monthly target trials using All of Us Research Program data from 2010 to 2023 to compare GLP-1 RA users with propensity score-matched controls. Eligible participants had MASLD and T2DM. We excluded participants with previous hepatic complications or other chronic liver diseases. The primary outcome was a composite of incident cirrhosis, hepatic decompensation, hepatocellular carcinoma, or liver transplantation. We performed intention-to-treat and per-protocol analyses. RESULTS: A total of 2,110 GLP-1 RA users were matched to 2,110 nonusers. Over a median follow-up of 2.7 years, 187 hepatic complication events occurred: 74 among GLP-1 RA users (13.5 per 1,000 person-years) and 113 among nonusers (21.9 per 1,000 person-years). GLP-1 RA use was associated with a 38% lower risk in the intention-to-treat analysis (hazard ratio, 0.62; 95% confidence interval, 0.46–0.83; P = 0.003) and a 42% lower risk in the per-protocol analysis (hazard ratio, 0.58; 95% confidence interval, 0.42–0.80; P = 0.001). Subgroup analyses by baseline fibrosis-4 and body mass index demonstrated consistent directional trends. Landmark analyses at 6 months were consistent with the primary findings. A negative control outcome, incident fracture, showed no association. DISCUSSION: In a nationwide, diverse cohort of individuals with MASLD and T2DM, GLP-1 RA use was associated with a reduction in hepatic complication events, supporting a potential hepatoprotective effect in real-world clinical practice.